NR

TraderJones89

GDV up quite significantly here, which means revenues will be coming with that as well. This is a nice NR to read after this current beating as the market pulls this one down with it for the time being https://www.businesswire.com/news/home/20220511005642/en/

TakeMeToYourSeder

Just saw this NR in my email and thought to myself, “ahhh, that’ll be good for a few negative percentage points on the ol’ shareprice”

fufm

I like to see a previous high or low be broken. You can sometimes see that a break is likely to happen and get in preemptively but the confirmation is the breakthrough of that previous level which signifies something in the market’s sentiment has changed and unleashes the thing to move outside the consolidation. Usually this does come with higher volume and you want to look for that. I think of volume like an “authenticity” gauge so the more volume, the more you can trust the move. A good example of this is today on QQQ. It’s not the exact same pattern but it’s a similar concept. Here is the chart: https://imgur.com/a/xwg3NR3 And here are my terrible scribble reference points lol: https://imgur.com/a/wkAe9F9 So you have the initial trend (blue line) from the open until about 11am that’s just a straight bearish downtrend. Weird because of how strong it popped ah yesterday with FB so you kind of expect a reversal… Which you end up seeing the *potential* for (not 100% yet) on that move right around 11 where it breaks up and breaks past the previous high of the blue trend. (This is the start of the white line trend and the #1 point). Notice how it gets beyond that last blue high point before moving lower. Now the second datapoint suggesting a reversal is a higher low relative to the previous low from the blue trend. That’s point number 2. This is when you can start to get in “preemptively” like I was saying before. You now have a support against which you can set a stop. Still a little flimsy but more risk, more reward. Then the case is basically closed at point #3 when a fresh high is put in beyond the previous white one. And then later even more so when it just slices thru the HOD like butter. This is where you can get in for sure if you haven’t already and/or add on. This same principle would apply to a consolidation wedge. You want to look for the break of that previous high, ideally a higher low to be put in, and then a break of that last higher high. Now sometimes you just get a break of the prev high and it runs to the moon so you can just sometimes get in at the beginning but like before, the more confirmation you have, the less risk. But reward also typically scales back as well.

silicapacks

https://www.youtube.com/watch?v=NR1465geajU

Phorensick

Credit Suisse note on Bretton Woods III https://plus2.credit-suisse.com/content/dam/credit-suisse-research/SearchPDF?DocumentID=1191091&DocumentType=NR%2520Publication&documentClick=true&AuthRequired=true&tagFormat=PDF

longGERN

Ok keep going paying tax to the US for no reason. If it was real property in the US an NR would be required but not stocks...

longGERN

Why the fuck are you sourcing capital gains to the US if you're filing a 1040 NR?

QuirkyAverageJoe

Tell Uncle Sam to accommodate filing 1040-NR electronically along with capital gains and other forms. Sprintax sucks!

TraderJones89

Yeah man, that's what I had hoped with this one and glad its getting to a lot of eyes. This company has so much promise and is a NR or two away from really exploding imo

Royalcanuk

Long and strong. Got in for the Battery Recyling tech, and their exploration side (ie. Mani) is icing in the cake. Ultimately I'm hoping the EVSX side bankrolls their exploration side seeing the most recent drill assay NR released last week 🙏

stockly123456

This is why fx reserves will slowly move into other things that cant be inflated away - read [zoltan](https://plus2.credit-suisse.com/content/dam/credit-suisse-research/SearchPDF?DocumentID=1191091&DocumentType=NR%20Publication&documentClick=true&AuthRequired=true&tagFormat=PDF)

Blacktheripperuk

WHAT? Have you even seen the data on SST? Over 400%SI, Almost 900% CTB, millions of FTD. NR1 shortsqueeze list, threshold. You cant even compare it to ATER.

garbagefinds

Yesterday Chucky farted and the stock went up 5%. Would get interesting if actual news came out on the heels of this NR

OGprintergreenspan

Many believe [Euro](https://plus2.credit-suisse.com/content/dam/credit-suisse-research/SearchPDF?DocumentID=1191091&DocumentType=NR%20Publication&documentClick=true&AuthRequired=true&tagFormat=PDF) is fucked too.

NegativeMoose5

The US has already embargoed russian oil (which doesnt really have any effect as the amount of russian oil entering the US was negligible pre war). Embargo means that its banned from entering the US not other countries. If the US wants other countries to stop buying russian oil, they would have to sanction them. I dont think this is feasible as sanctioning China would have a detrimental effect on the global economy, and they dont want to alienate India/other SE asian countries as that would push them further towards China. if you want more info on this, you should check out the below article [https://plus2.credit-suisse.com/content/dam/credit-suisse-research/SearchPDF?DocumentID=1191091&DocumentType=NR%20Publication&documentClick=true&AuthRequired=true&tagFormat=PDF](https://plus2.credit-suisse.com/content/dam/credit-suisse-research/SearchPDF?DocumentID=1191091&DocumentType=NR%20Publication&documentClick=true&AuthRequired=true&tagFormat=PDF)

Thanos1901

https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf?utm_source=Social+media+post&utm_medium=Paid+Posts&utm_campaign=BitNile+Spartan+Capital+Announcement+&utm_id=Spartan+Capital+Report+&utm_content=March+2022

Zealousideal_Tax_609

https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf

harrypotter5460

[Spartan Capital](https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf). There’s a lot of things going for them.

harrypotter5460

The price target comes from Spartan capital. See [this](https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf). I can back up my claims. On the other hand, no one in this comment section who has shit on $NILE has backed up their opinions.

JezboWilkins

Some DD on $NILE https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf

JezboWilkins

https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf

Downvotes_inbound_

Analyst DD: https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf In short: Company revenue gonna be $160mn+ ( way more if btc spikes), market cap is only 65mn, super undervalued. Adding 2k+ minimg machines every month for 6 months. After that adding more green mining machines. Special dividend for investors coming soon. 4/14 earnings projected to be very good. In the EV market via owning a large portion of MULN

Dangerous-Refuse-280

[$7 Price Target](https://dluguzmjfx166.cloudfront.net/public/NR_NILE_03082022.pdf)

Frequent-Context-183

Nine energy. TLSS and NR PFIE and ENG

rackymcdacky

Try watching this interview, Shadid talks about how he sizes his positions to avoid big losses, for example I try not to hold a full position at more than 2% loss over night. https://youtu.be/NR4S_entRDI

Ronafied2020

Weird they didn’t release an NR for that, but yeah me too

Mister_Rahool

Pointing out concerns in a fake NR doesn't make me a "troll," but you @'ing me in a 3 month old thread to spread shit about your pyramid scheme co. makes you look pretty shameless

Frequent-Context-183

Time to pump NINE and PFIE. Also NR and TTI good oil services. Ensv is a good pump too

Frequent-Context-183

Can’t go wrong with energy and commodity. Even a crayon eating retard knows that. NR nine

Frequent-Context-183

Oil services still cheap. Y’all regards probably missed the boat on klxe and nine. NR and TTI still decent

MonoRailSales

If SpaceX [Starship](data:image/jpeg;base64,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) is not nick-named "broomstick" I will be sad.

TakeMeToYourSeder

Not seeing this on TD web broker. Was this is an NR or something?

-Winnie-the-Pooh

palantir will be the NR 1 defense stock of the 20s

Boobooowl

When tsri got to 99.9x % score, it plummeted from 15 dollars to 10. Fintel is an algorithm, if it worked you would just need to buy every NR squeeze and you would be a billionaire in a year. Squeezes need a market tailwind d, where overall direction changes to favour your stock. I wish it went up but you need an economy shift which is not happen g here.

Creative_Ad_8338

Not sure what company but I think it will come from synthetic biology market. McKinsey reported that 60% of global market inputs can be generated by synthetic biology. Amyris (AMRS) has a huge IP and technology lead. Their COVID nasal spray vaccine, in partnership with ImmunityBio, in phase three clinical trials should hit market later this year. Study will also validate their squalene production as pharma grade and they will likely be the cheapest, most abundant source of squalene for vaccine makers, and other pharma products. Pipeline of new compounds is accelerating because their platform becomes informed with every new strain build via AI/ML. Their vertically integrated product portfolio of JVN, Biossance and Rose is growing rapidly. Overall, Amyris should be stable cash flow positive this year with additional plant coming online. They've reached the inflection point. Amyris also has nicotinamide NM and NR in their pipeline. These compounds exhibit significant anti-aging potential and could prove revolutionary to healthcare. Long term studies are underway. A few links below about these compounds, as well as great video from Bloomberg that discusses the science and potential. Also, US strategic command has launched additional trials with these compounds on special forces. Amyris will be the first company to produce these compounds with purity on scale required for mass adoption. Amyris also can produce many cannabinoids on massive scale for minimal cost and time compared to cannabis growing, extraction and purification. They've also patented applications for usage in new products like Teresana, which recent clinical studies show the formulation of squalene and CBG are the most effective acne treatment on the market. They also discovered it to be effective in treating arthritis pain, and patented applications in inflammation and arthritis. This is just the beginning of synthetic biology. Market has yet to fairly value intangible assets so any of the synbio companies are at massive discount. Synbio allows rare compounds to be generated from cane sugar inputs. It will be hard, or impossible, for specialty chemicals companies and traditional extraction based companies to compete. https://www.harvardmagazine.com/2017/09/anti-aging-breakthrough https://www.bloomberg.com/news/videos/2021-02-12/meet-the-scientists-trying-to-reverse-aging-video-kl2hwt15 https://www.genengnews.com/news/u-s-special-operations-command-to-test-anti-aging-pill/ https://www.mckinsey.com/industries/life-sciences/our-insights/the-bio-revolution-innovations-transforming-economies-societies-and-our-lives

mabjab

XCUR is too much of a risk, BBIG may turn red this coming week, don’t know much about VT NR. SENS is a good short term and long term play and is the best choice to day trade.

garbagefinds

Copy and paste from a recent convo: "Anyways my 2022 picks are $SXOOF, $ATBHF, $NEXNF. $NEXNF does compostable coffee pods, and also has the potential to branch out into other compostable products. As of their last QR they had 45m in cash and little debt, and currently have a market cap of 60m. Coffee and other pods are now available on popular online retail sites, and will soon be on retail shelves... I forget where. The stock got pumped and dumped as often happens with newly listed (as of Dec.2020) companies, seeing a high of 5.90 in February... the price is now .60, which I consider a bargain. $ATBHF is an exploration company mostly based in mining friendly Virginia (no permits needed). They recently announced discovery of SEDEX-style mineralization which seems to have excited the geology nerds. They also have some interesting gold potential, and one of their main advisors is Don Taylor, who won the 2017 Thayer Lindsley award and seems to be pretty bullish about this area. Otherwise, I like that CEO Tom Ullrich lent the company his personal money, which allowed the company to do a raise at much more opportune time (post SEDEX NR) which by my calculations reduced dilution by at least 50% (raised at .06 CAD instead of .04 at best) which I appreciate as a shareholder. Anyways, this can boom or bust, but with a market cap of 10m the boom would likely be much more profitable than the bust. $SXOOF has a lot of stuff going on. Most recent hype is about its Manicouagan properties, which insiders feel could compare to the Voisey Bay discovery which sold for around 4.5b in the 90s. But besides that they are looking to use their lithium / battery processing tech to open a battery recycling (lithium batteries especially, but others as well) plant in Baie Comeau, QC, which is likely something the fed & provincial governments will want to publicly support. And based on their tech-related NRs to date, there's little reason to doubt the process. A recent raise at .55 (FT units) to support their exploration operations was bought up almost exclusively by insiders and institutional investors Sprott Assets, Maple Leaf and Marquest (current sp - .43). Lots of other little stuff, like a purported ability to produce hydrogen & fertilizer as byproducts from the lithium/battery recycling operations, a "confidential agreement with two aluminium producers" to sell their recycled aluminum to (and from the wording of the NR, which contains plurals and singles, it's seems likely to me that the companies are Rio Tinto & Alcoa, through their Elysis joint venture), their deal with $ICM to process their lithium (and that project seems to be finally getting somewhere as well)... anyways, based on all that $SXOOF is my "get somewhat rich or get injured trying" pick for 2022. I feel pretty good about the lithium/battery stuff alone, and if the exploration stuff is anywhere close to what insiders hope it is, it could be a very explosive year." Also shoutout to VVIVF, an organic fertilizer play that's starting to pick up a bit of steam.

Fermi-Diracs

SPY 451c 2/4 (0DTE) OPEN at 0.21 CLOSE at 1.95 https://imgur.com/a/NR2bg9Q

TakeMeToYourSeder

Yeah, I was thinking it definitely isn't a sign of a buyout because they'd get hammered for improperly releasing material news, so I crossed that off my list. The strange thing was it hasn't been released, and I can't actually find it on their site apart from that direct url. Saw it on twitter but I'm not sure how that user found it. My guess is they're just going to release an NR supporting amazon's decision to back the Mace bill, but for whatever reason the draft was visible. Long story short, who the fuck knows.

kn1f3party

And me https://imgur.com/a/HW7NR4O

Turbul

Yes but I don’t see any NR ?

ChronicMasterBlazer

I feel like we’re going to reverse soon, and it may be a NR completely out of left field or it may just be shorts finally covering… who knows but I’m staying optimistic. Let’s all manifest a very GREEN start to 2022! One love all. This shall pass too. We’re in the eye of the storm, it is bad out there. But we shall prevail. ❤️

former-Ronnie

https://youtu.be/NR_ZVzrTeYk Wooooo weeeeeee trust the science 😂🤡🤡🤡

theherostory

Taiwan NR 1 

FamousFaps

Medivolve Inc, NEO: $MEDV OTC: $COPRF Looking to have a huge Q4 and Q1 for 2022 (Q3 was $25 Million) Should hear about their telehealth transition in the coming months. 2021 Q3 Results NR: [https://finance.yahoo.com/news/medivolve-announces-q3-2021-results-225500716.html](https://finance.yahoo.com/news/medivolve-announces-q3-2021-results-225500716.html) Nov. 10th Investor Webinar: [https://www.youtube.com/watch?v=HCE2REFBD2U](https://www.youtube.com/watch?v=HCE2REFBD2U) Key points from Medivolves Investor Webinar (Credit: AGStockPicks on twitter) \- New CEO joined May 1 2021; found it to be in financial distress with $20M+ in debt, $100K cash remaining, losing 150k-200k per week. \- Saw opportunity in COVID-19 testing that was generating strong revenue. Cut money losing projects and expenditures and tightened up overall spending. \-Saw an overnight 78% increase in foot traffic at testing sites. \- Transitioned from cash based model to insurance base by implementing a new software suite. The changes allow the company to connect to 700,000+ different insurance companies and replaced 20-30 in-house employees. 99% of the US population qualify for free COVID-19 tests under this new model. \- Rolled out second software suite to streamline patient registration online. \- By Q3 2021, saw 3,000 patients per day (18,000 per week). $180 USD per patient = $3.2M USD per week gross revenue. \- Currently seeing 6000 patients per day and operating at maximum capacity. \- Looking to add two more COVID-19 test to the existing testing package to bring the per patient revenue up from $180 USD to $410 USD by Q1 2022. \- Q4 2021 revenue is expected to be as strong or stronger than Q3 2021 \- Beginning transition from pure COVID-19 testing play into AI/Telehealth with 5-10 new pilot sites opening in the next few months. \-New platform will target testing for COVID-19, flu, diabetes, cancer, stroke risk, and more. Goal is to use the AI and Big Data to disrupt the US healthcare system by streamlining registration, patient sample collection, on site and at-home visits and doctor referrals. \- Conservative estimate for 2022 gross yearly revenue: $200M - $300M USD. \- Main competition: TeleDOC ($16.2B mkt cap). \- NASDAQ uplisting in 2022. No immediate reverse split . Will concentrate on growing shareholder value. \- The company has received and rejected 3 buyout offers in recent months. That was before the record breaking financials were out.

tykogars

I’ve got 4 lotteries right now, 3 under 0.001. Pretty much like you said, threw some darts and basically picked the ones that at least appeared current/active with NR.

whatisliquidity

Love SLB but they've got earnings Friday so worth keeping an eye on. HAL is well poised on natural gas, oil and defense. If Russia invades it might see some action. I little sleeper I like a lot is NR. Well ran and leaf by a former SLB exec. Nice moat, nice niche worth a looky

VisualMod

>Testimony by Governor Brainard at her nomination hearing: [go.usa.gov/xtjTb](https://t.co/z7Tz30DiON) \>Watch Live: [banking.senate.gov/hearings/01/04…](https://t.co/NR9uFQ8u1W) ^Federal ^Reserve ^[@federalreserve](http://twitter.com/federalreserve) ^at ^2022-01-13 ^10:00:09 ^EST-0500

BIGMEECH_300

Next earnings will drive thru the roof with our other acquisition taking off too plus new products that rolled out last year!!! Looking to cut more COG and boost NR and NP— feel like buying $300 on a June call 😤

LokiPokee

Better yet, buy calls and book every room in every Hilton hotel from March to the end of 2023. They put out a big NR about huge tendies coming in. Cash out the calls and switch to puts then cancel all the bookings. 2x win

ChronicMasterBlazer

Soooo, surprise diageo partnership? Come on spicy Monday NR 🤞

Qs9bxNKZ

That’s not how it works. You choose your residency and from that point forward, you’re not liable to the CA FTB for future “donations” If the CA FTB wants to come after a non-resident, let them. It’s like NY suing Elon because his Tesla ads are present - let them. Accumulation of wealth in any jurisdiction doesn’t give that jurisdiction leverage over that wealth. Again, if you leave a jurisdiction, it’s up to them to come after you and sue. Most people just file a 540NR when they move to Nevada and back date the form to Dec 31 of the prior year. “Mr Musk, we want you to show up in Sacramento to defend yourself against a tax claim, otherwise we are going after assets in the State under your name” “ I already sold my CA homes and my bank account is under a trust, as are my current holdings. But please, talk to my multi-millionaire lawyers once you can figure out how to get me to show up in CA. You already tried to arrest me in Alameda County and look how that turned out”

TheGoat81

Hopefully a juicy NR

tykogars

THRM.V, I’ve posted elsewhere so you can look at my history but basically a 15 minute antigen saliva test for Covid. Very deep into Phase 3 with FDA, results should literally be any day now. In the last month they’ve upped their manufacturing abilities to meet FDA requirements for emergency use approval (2.5 million tests per month to be made across 4 manufacturers) and just the other day a NR indicated the FDA confirmed their test is also good for detecting Omicron variant (huge news since it’s been in phase 3 for many months before even Delta I think). Current SP hovers around $0.40 and with FDA approval I see it popping big time. Hoping mid January the latest, but I check frequently.

tykogars

I guess it’s more diagnostics and maybe not so much biotech but THRM.V (ThermaBright) is a company that is currently awaiting FDA approval for a 15 minute antigen saliva test for Covid. Yesterday they announced that FDA confirmed it does detect Omicron variant. Within the last 2 weeks they’ve upped manufacturing capacity (pending approval) to 2.5 million tests monthly (mandatory minimum for emergency approval I believe). It’s impossible to say if it will get approval, but it’s been in phase 3 for many months and all NR I’ve read lead me to believe discussions with the FDA are open and generally positive. Speculation is that the approval (or dismissal) is literally a few weeks away, tops. With all governments shifting huge focus to rapid testing, for me a 15 minute saliva test that you can effectively DIY would be an absolute winner, especially considering SP at time of posting being $0.39.

bigsmackchef

I just did a simular search and found a variety of numbers. The website that I saw that claimed 700k also says they opened in 2018 which isn't true. I guess I'll have to wait for an NR from tilray or the next earnings release that includes it to know for sure.

newplayer28

We would’ve been green either way today, just a bounce from the lows after going down for months. The timing of the NR is just perfect

kiwimancy

Passively managed funds beat actively managed funds by the difference in fees on average, because they both hold the same aggregate portfolio of stocks and actively managed funds are all competing against each other for a net zero amount of alpha (before fees). More importantly research suggests that it is very difficult to identify funds that will outperform in the future based on their past performance. Still, a substantial fraction will outperform their benchmark over a 1 year period, somewhat fewer over 5 years, and fewer over longer periods. NN Duurzaam Aandelen Fonds appears to be tilted towards growth stocks (https://www.morningstar.nl/nl/funds/snapshot/snapshot.aspx?id=F0GBR04B2T&tab=3), at least currently, which likely drove a majority of its returns over blend style indices like S&P 500 and its benchmark index MSCI World (NR). It also outperformed the morningstar assigned benchmark index MSCI ACWI Growth NR (https://www.morningstar.nl/nl/funds/snapshot/snapshot.aspx?id=F0GBR04B2T&tab=1) over the past 1/3/5 years, but not over the past 10 years.

GodsSon1985

What’s the minimum to satisfy your needs to make it NR lol

alexparker70

EanEJsNHtPeguxceGcdKtKEZ HJ9yGqTxFK6TMZPruMHPuUsk G6X9weVvcHcAg7h2r7Mqd7mT hXVHztmPLmBXyxxEKXm2JX7x AChUPpeAqXsHXvcRqCrvdCU4 WcTdmstTYEhB5yxTx4hGzmqf 39Z9hbBmrNVmsZVEktmDdsBf QhARJefRMnUUjhG5UXckHC69 VbbdQqKbanajTvxk7E6CnLkw jQKtwQytDPrbaNFLefKXurDG jwAPXeqbT24NKaG95YXNGjQh mgsT9TySZRR5BCGJ5Ezt7h96 vBH8Y6tCHYEEb5bL4SWvubkq BzyG9ujysVzvhbTqw3QXsSD4 juDZ4bJbyCZGuEkt49gcprpv dg8Y6BYf7Y3pHmpZndKNFAXD Ea52ngJXWp88z6eApXbcBGLJ TGCBFAAPN3cuA5UrpW8w33Th 7qpdz2P3RBh6yLufvAdyYhKM YrD32NGkDrAQVTttEVxfKRas J5BEu6XqBdxWaz66p64XQLst jv8NR2YHS4v2rFFRPYHJatsy EfG9sapWDUEhvpWFRLDUpwMq 7hhHA9EY27y4pzWmmghpsuAk 6SxzRF8uv6juvdkm8meyP8hJ QHRjmS8dFnCA8wcuuYUUW4b3 YkyQXybPQYJDDf8TdTG9ykAg f699TAR5LfZNXPHNzWBzp6Yv mF9fY7AbN3JtAWNj8JZ4uKVt BrS78K8Xve4Te7JRD9FsJyzF vfmWY3Q6PSMGZDdGVnLKvNXw TEKnUhT4g2QKCCG9NsfLqsMH LvarUuqrPwzczfeSw9ENJKYG ymfbG5XcMNBvmbZcVvjppkvN dJAH7ZSSj3ypaDmxC4jtr3yr 6GzskRhwP9ZYEGyCCARYHyne gcyErkpNnd63EnTF54aXd4d3 6CNQWHpTTgQXcaQ37h5yuwWH 7Ek6Uk4jMJ7y57sVPfaNAM6n yzcrPR2UVsCYNeNux3QZrMnH nXkvsDZKGXkpCShJHt3qwYPX 9HSKXNYV4ugZpY4uBvpvEKpD T3Hv3JrkLEWeBT7TfF5hnYe3 Gn8erCdJjSbJXduaNhst85cx PW3s7V95644rczEjTN8dPNYk V4UL9EAZKRUzty5xUp3LFhTk wrUdqvLPDfwh7GU2sJ6NbtmX 9S9v2dCUH8KkBYhRkCndPmEy y3TTAnbPcBhyCWHdQsdMYkCK mqy6M8sdM26EsySqb7ef5PyY vttaMkQpQjFXqVhSmX7VwWGL U6U72Qs5ecGLZKHSZxYHeDWS jFRp4zvdfU6mpqwPR9d5T2np FaYU8QPZMJJ9Zjz6gRjJ758q ybqdLDxPAJBGFyMTzEUYwPUU M22maguhhknsR7jCCGNKF7Z9 eTknaap8heTqA8sbesy4JccF sxg8wUzhrdUC2KLdAHDMwTHd LknQuPCfxxZ7gf4WQUEm74q9 zbEvENSZpFmSgD4KtbHYAqVs wEhVJhbeaXcQr2ZvMGJv3ZaH q4hG49cfdcVy8SzYPjvp9NB7 W757QA3AgE7c2zK3y59vEUVH S335v6nBhKGZhC677gFvLUkW VkGDA5yPSgJTLg3uP67DcuLP xgZexaJQwZvKcjUjA4RJXMt6 G7hYnedQAsNpLVYLLDbKs2L4 bvMwwFKEFPTWX86bWFBEJHrz v4BTQU4kbCsqcphx8JMJrnUu W3Pj2Uedj6XE6BaQjtnxDHdh E5F9y8M586jZhEknmsMPqruF vHJnf8YHAxpquzxXeH6Eprzw 2WgpBU9dVe7P9sxyzVe3RbHn VjaGNBfXATca3BHSKPJNFEvx bHDBKTYZQ7QtMBUxmq2nVAVK sfKKGNqthX4YJzRHsuw7hK96 JTcW3U9fTC7yph47z26GqXXx vUEJCpEAs6QRfKUEyXgJDFUy VuXyXYK7cLvNsHLA5MaYCumB nhtsWfpSYnFcE5xfFGtrC6GA SaBxg4nf8HE32u2bfVKnD7d9 cXwSGAxMCAFeqbJ3Dy6U8gJn wDMEK2UvWWMQxdNLvU4TBHbD bWELbmYLSB5njy5zfpjZYVPE G4YqXBXE2hcXxJhvCvktvsDP AVKsf3u9naG59LArWM8nJsdx 6wVYYxyfZxuEp4msAbs7K6u9 zRVCaxF84y6dFDBARmGYftgR XGBQ4VWUEsxQKhWA4H6wMVza 5rjGqcAMEtQVcCPJh9QF7F96 2n45jGcJxU5SjHyK4umDXz3q UfCn34SwRC5yRcxBC2P8PB8X uAzLBV6CqVTzPXyRVHNsscYb MthSXFqtmWZkFtcYLuk3MwmP XN4UCVQEAGyD7rcuFMjxY3A2 aHmbdrU2zzwhbQQvmCjXdNgm mE4hn4etFGAuWtdbvgX8BueN ZDpR6K3V6Wjt3JhHhqDKae5a HYAybDkCTnLfVCKPEuwtTCXZ Yv2z24dXS8Zb5TmUXcwSfkzk

Snapp12

You can drop the quotes lol you now have a NR stating the trials for their flagship drug is progressing well with noted positive effects. Do wonder why sp still in the clapper though

tykogars

I’ve got a small position here and I wish I had the funds for more. If one of my two main holdings see any spike I’ll be selling off and getting more RVV. I don’t think it’s going to be a very long hold before it either pops right off or just flops, but everything I’ve read sounds very promising. I’m also holding THRM.V and am under the same impression. That particular stock IMO is make or break within 3 months absolute tops. It’s literally just waiting for final FDA stamp of approval. They’re so far into phase 3 that the last NR indicated FDA wanted additional study/data on the point-of-care application, which I’ve read is essentially ease of use/how clinical staff handle it. Considering it’s just a spit test I don’t see how this could be a major issue in any way.

Banabak

No one talks that rates are at the floor , where else you will put money if you investor ? 10 year at 1.6% or let’s say msft with high PE but paying dividend , doing buybacks and still growing business? Discount rate on NR of the most important driving factors Bevause all asset classes compete with each other

EducationalQuarter30

Congrats to those making bank on CIFR, but please keep in mind that it hasn’t commenced operations and the only NR I see for mining equipment says they won’t even START receiving them until June 2022. Manage your risk.

sitbar

battery recycling plant going live this month, drilling campaigns for Li, Cu, Ni, and other rare platinum group elements, lithium extraction from spodumene. With their NR last night, they announed they're able to recycle old ICE batteries as well, being able to fully recover and recycle everything from the black mass's of ICE batteries. Compared to their peers, SX, despite having far superior tech in terms of recovery and recycling, and having a recycling plant thats essentially ready to go, is far far under valued. This is just small portion of the reason why SX is gonna blow up. It's been doing really well the past couple of days, so maybe a slight dip today but not much and just for a short time.

buyinghighsellinglow

In July there was a [NR](https://www.newswire.ca/news-releases/canntrust-announces-court-approval-of-plan-of-compromise-arrangement-and-reorganization-828480024.html) about how they're trying to get the OSC to revoke the CTO and get TRST relisted. No news yet though

derbs361

NR about to 🚀🚀🚀

derbs361

Check out NR going to rip higher as energy does!!!!!

ChronicMasterBlazer

Don’t hold your breath for CGC earnings 😬hopefully they have a nice NR to soften blow

ALL_IN_HAYSTACK

Thanks for sharing NR! Here's the short thread combined: >A short seller goes after Ginkgo Bioworks > >[Screenshot of Scorpion tweet, link to PDF, & link to Bloomberg article] > >The short seller cites many anonymous people saying negative things. Interesting difference with journalism, where as a rule one ought not allow anonymous people to lay down critical fire. > >Investors often look for catalysts---coming news, events--that will move a stock to the value they think it has. The short seller thinks $DNA should trade for less and will make money if it does. But what is the catalyst? > >Ginkgo has many many R&D deals, many with long horizons. So there is no one catalyst, like a single product that succeeds or fail, that can put $DNA market cap to a test > >In this case, the short seller may be using his report as the catalyst--he did make the stock dip, looks like, but it's impact may be short lived. Or maybe he is trying to provoke an SEC investigation.

beng1244

Can't wait for the "received positive feedback" NR in 3-6 months lol.

theherostory

Taiwan NR ONE

CatSE---ApeX---

Starlink may be used for navigation, yes. SpaceMobile _will_ be used for navigation because it follows the standard 3GPP 5g protocol. 3GPP 5g protocol release 16 chips and later release 17 chips include positioning using several techniques. Uplink and downlink sounding signals as well as roundtrip time and angles of arrival. This means together with the extreme signal strength at ground level and the crypto functions of NR that AST SpaceMobile constellation will provide spoof and jam proof highly accurate positioning / hardened PNT / fused Leo GNSS as it is just part of the standard protocol they use.

10xwannabe

I'm in Desert Mountain and if your interested this is the time to do it. It just dropped 35-36% today after announcing positive Well 4 results of He of 1%+ and they confirmed it can be commercialized. Well 1 and Well 2 had results of 7% and 4% respective. Well 3 is in some litigation with the city of Scottsdale which they should win, but have not commented on that one due to current legal issues. That means 4/4 on drilling are positive. I am assuming HUGE drop today came from underwhelming 1% HE this time around vs. the other wells (Wells 1 and 2). They also said production via their own processing plant should be in 2022. The thought has been Q1, but there might be some anxiety if it is delayed later and that caused the drop as well. Unlikely to be true, as it looked like q1 2022 before Well 4 results which they said is somehow geologically structured to be easier to process and speed along the plan to produce. So can't see it further delayed, but lack of specificity in the NR didn't help. Will take some guts to invest into a major drop, but this one makes little sense since it was a positive result. If (big IF) you are going to do it I would do DD and do it soon as these are BY FAR the lows compared to last several months.

modsaregayasfukk

Broodwar is fucking amazing. Spend so many hours playing on ZC NR20 games and Bunker Defense lol

TraderJones89

This was their NR from earlier this morning outlining the LOI for 10 additional clinics https://www.businesswire.com/news/home/20210909005726/en/Revitalist-Lifestyle-and-Wellness-Signs-10-Additional-LOI%E2%80%99s-to-Expand-Clinic-Network

RodneyGK

Seems an NR that nobody gives a fuck about.

dreamgreener

Just reading the original NR and doesn’t say only the lockup periods Looks like a very good acquisition by Cresco top 3 in the state

hunter994

https://youtu.be/TJ13BA3-NR4

bheal

That's ambitious. I recall a thread from NR months ago where a Rolls engineer came out and said that internally they don't expect to go over $2 this year. I grabbed some when it dropped past 1.30 and flipped it, but I'm not looking to wait months when I can just use that money on SPY calls/puts as the situation dictates.

Kbarbs4421

I'm on mobile killing time. Too lazy to revisit the NR and crunch the numbers. Iirc, the Serruya deal does not offer warrants. It's straight shares at $0.24 USD, compared to yesterday's close at $0.27usd. The warrants you saw might be tied to the amended GGP notes that Tilray bought. Which are not new, but rather amended. Haven't compared the original terms to the new terms on the GGP (now TLRY) debt to see if potential dilution increased there.

okay_thatworks

i'm sure a lot of you use ceo.ca for capturing NR drops -- looks like the founders sold it for C$11M

EcoTech_Watcher

AKMY closed on Friday with 6.38% gain thanks to their NR : [https://finance.yahoo.com/news/alkemy-launches-innovative-100-recycled-185200508.html](https://finance.yahoo.com/news/alkemy-launches-innovative-100-recycled-185200508.html)

jameshayek

Not true. 5G NR1 for current sub6 bands use the 5G Physical Layer over the 4G Evolved Packet Core. The issue is the bandwidth available for most NR1 deployments today. (AT&T has 5MHz BW for 850) TMUS has >100MHz for Sprints 2.5 band.

m3g4m4nnn

Better luck next NR, pal! ..but I gotta warn you, there is some serious competition for Top Tetra Hater around these parts.

UghImNewHere

The founder of Marvel Diagnostics announced via Twitter on Thursday that the first commercial delivery of BlowFISH, a revolutionary respiratory health tech, was happening on Friday. Medivolve (MEDV) owns 13% of Marvel with an agreement in place to own up to 40% of it. Expecting NR tomorrow morning: www.twitter.com/PirouzKavehpour/status/1420934698725896196. This could easily send MEDV to $0.25 CAD minimum once enough people realize the potential behind this technology, especially with Delta grappling the States. MEDV was trading above $0.40 the last time US cases were above 100K. They’ve done an offering and placement since, but factoring in the current float size, their clinics, testing numbers, etc., this should already be $0.15 CAD before any BlowFISH news.

ICT_Guy

Hello, At the moment I'm investing in NN Enhanced Index Sustainable Equity Fund (ISIN: NL0012125736). It is actively managed (0.17% fee) but it tracks the MSCI World (NR) index. The only difference for the fund is that it excludes certain companies (weapons, tobacco) so the focus is on sustainable. I read a lot on the negatives on actively managed funds. But I think most of those arguments don't hold true to this fund. Since it still follows the index but it excludes companies I don't want to invest in anyways. How do you guys see this?

ajile1976

\---> "The Agreement will form the backbone of the Company’s Phase One launch of its cryptocurrency hosting and mining operation in Georgia. Further details related to this Agreement will be discussed in the near future." This NR is vague...investors would feel confident if they explained how they are going to get to 200M...did they secure miners? There are great companies that already have miners installed and generating revenue. $LNK $LGLOF comes to mind.

Snapp12

Read the NR lol

mic_sco

Think you need to file a 1040-NR to show the interest, Dividend and capital gain transactions.

ComfortableSpeed1834

NR2F6 nuclear receptor subfamily 2 group F member 6 [ Homo sapiens (human) ] https://www.ncbi.nlm.nih.gov/gene/2063

ComfortableSpeed1834

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade https://pubmed.ncbi.nlm.nih.gov/29670099/

Snapp12

Don't know if its as clear cut as that, if it was that bad they could just increase the site count. Expanding to 2 opioids (that are stronger) is curious because they have to wait a few weeks before the DEA completes something on their end (stressed as a formality in the NR they'll get it). If they were trying to speed this enrollment up adding sites is the easiest & fastest way to do it. Not saying you're wrong, but until more news comes out its hard to say either way.

EagleEyeStx

BABY.V with a big NR that just went live, coming on the heels of a brief interday dip, these guys are gonna ricochet back over 3$ this week if not today

Recycle-Reuse-Reduce

$INNPF hit ATH after new NR 👇🏼 https://finance.yahoo.com/news/innocan-pharma-announces-filing-international-200000642.html

Teekay53

Centralized government power did wonders for China GDP. It's rapidly growing and it is a huge superpower. However, there's rampant corruption, and imo strong authoritarian centralisation will lead to doom sooner or later. USA NR. 1 FUCK THE COMMIE SWINE

magnetsandbananas

UPI Company is tailoring them selves to bring in huge $$ and 5x their current SP. 5+ sales contracts from 1million to 10 million in June alone. They are in air purification market as well as capitalizing on any niche products they can bring to market. So many NR come out each week and the entry price is super low right now

PickIeRickthe2nd

It sounds like you are able to recite a NR pretty well but can’t see through the fluff of what it’s actually like working in a facility that “ensures they have significant control over what they produce”. Do you even know what that entails and how it compares to other companies? Good genetics. Whatever. Which company doesn’t have good genetics? It’s all smoke and mirrors to distract the common investor. The reality is you have a bunch of kids aged 19-25 with zero motivation or experience in the workforce being led by by people who still think drinks and soccer moms are the keys to success

planikaraj

ADXS up 30% volume 123 mil vs 9 mil avg now sitting at 0.61 TODAY: Advaxis and Biosight Announce Entry into Definitive Merger Agreement – Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to Host Joint Conference Call on Tuesday, July 6, 2021 at 8:30 am EDT MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction. The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine (BST-236). The combined company is expected to have approximately $50 million in cash, cash equivalents and marketable securities at closing. Following the closing, which is expected to occur in the second half of 2021, Advaxis will be renamed Biosight Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “BSTX”. The combined company plans to advance its pipeline through multiple clinical trials, and anticipates the following milestones over the next 12-18 months: Topline results from the ongoing Phase 2 trial of aspacytarabine, which has completed enrolment, as first-line therapy in AML patients who are unfit for standard chemotherapy Recent data presented at ASCO showed that aspacytarabine achieved complete remission (CR) rates of 39% across all evaluable patients (n=46) with 63% of cases with negative minimal residual disease (MRD(-)) and median overall survival (OS) of 10 months at present (95% CI, 6- NR). Altogether these results are encouraging considering the high risk factors in this population at baseline; Results from the Phase 2 trial of aspacytarabine in collaboration with the European cooperative group, Groupe Francophone des Myélodysplasies (GFM) in patients with relapsed/refractory AML and higher-risk Myelodysplastic Syndrome (MDS); Initiation in the U.S. of a second, Phase 2 trial of aspacytarabine in patients with relapsed/refractory AML and higher-risk MDS; Results from the ongoing Phase 1/2 trial with ADXS-503 in combination with pembrolizumab in non-small cell lung cancer; and Results from the Phase 1 trial of ADXS-504 in biochemically recurrent prostate cancer “After an extensive and thorough review of strategic and potentially transformative options for Advaxis, we are very pleased to announce a proposed merger with Biosight,” said Kenneth A. Berlin, President, Chief Executive Officer and Interim Chief Financial Officer of Advaxis. “We believe the combined company’s strong and diversified oncology pipeline with late stage and early stage assets, near-term milestones, seasoned leadership team and focus on both hematological malignancies and solid tumors have the potential to provide transformative benefits to patients while also providing value to our stockholders.” “The proposed merger with Advaxis is a unique opportunity for Biosight to build a leading public company in oncology, with a diversified clinical pipeline in both hematological malignancies and solid tumors. The combined company will have the demonstrated expertise and strong balance sheet to advance its lead programs towards multiple anticipated milestones over the next 12 to 18 months,” said Dr. Ruth Ben Yakar, CEO of Biosight. “I would like to express my deepest appreciation to the wonderful Biosight team, including Dr. Liat Flaishon and Dr. Shoshi Tessler who lead our R&D activities, and Dr. Stela Gengrinovitch, the founder of the company. The excellent work and dedication of the entire Biosight team enabled the significant achievements. I would also like to thank our Board of Directors and Shareholders for their support over the years.” About the Proposed Merger Pursuant to the merger agreement, Advaxis will acquire all of the outstanding share capital of Biosight in exchange for the issuance of newly issued shares of Advaxis common stock upon closing, subject to the satisfaction or waiver of customary closing conditions, including the receipt of the required approval of the Advaxis stockholders and Biosight stockholders and certain regulatory approvals. Upon completion of the merger, Advaxis’s then-current equity holders will own approximately 25% and the former Biosight equity holders will own approximately 75% percent of Advaxis’s common stock, calculated on a fully diluted basis.

planikaraj

Update: Advaxis and Biosight Announce Entry into Definitive Merger Agreement – Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction. The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine (BST-236). The combined company is expected to have approximately $50 million in cash, cash equivalents and marketable securities at closing. Following the closing, which is expected to occur in the second half of 2021, Advaxis will be renamed Biosight Therapeutics and is expected to trade on the Nasdaq Capital Market under the ticker symbol “BSTX”. The combined company plans to advance its pipeline through multiple clinical trials, and anticipates the following milestones over the next 12-18 months: Topline results from the ongoing Phase 2 trial of aspacytarabine, which has completed enrolment, as first-line therapy in AML patients who are unfit for standard chemotherapy Recent data presented at ASCO showed that aspacytarabine achieved complete remission (CR) rates of 39% across all evaluable patients (n=46) with 63% of cases with negative minimal residual disease (MRD(-)) and median overall survival (OS) of 10 months at present (95% CI, 6- NR). Altogether these results are encouraging considering the high risk factors in this population at baseline; Results from the Phase 2 trial of aspacytarabine in collaboration with the European cooperative group, Groupe Francophone des Myélodysplasies (GFM) in patients with relapsed/refractory AML and higher-risk Myelodysplastic Syndrome (MDS); Initiation in the U.S. of a second, Phase 2 trial of aspacytarabine in patients with relapsed/refractory AML and higher-risk MDS; Results from the ongoing Phase 1/2 trial with ADXS-503 in combination with pembrolizumab in non-small cell lung cancer; and Results from the Phase 1 trial of ADXS-504 in biochemically recurrent prostate cancer “After an extensive and thorough review of strategic and potentially transformative options for Advaxis, we are very pleased to announce a proposed merger with Biosight,” said Kenneth A. Berlin, President, Chief Executive Officer and Interim Chief Financial Officer of Advaxis. “We believe the combined company’s strong and diversified oncology pipeline with late stage and early stage assets, near-term milestones, seasoned leadership team and focus on both hematological malignancies and solid tumors have the potential to provide transformative benefits to patients while also providing value to our stockholders.” “The proposed merger with Advaxis is a unique opportunity for Biosight to build a leading public company in oncology, with a diversified clinical pipeline in both hematological malignancies and solid tumors. The combined company will have the demonstrated expertise and strong balance sheet to advance its lead programs towards multiple anticipated milestones over the next 12 to 18 months,” said Dr. Ruth Ben Yakar, CEO of Biosight. “I would like to express my deepest appreciation to the wonderful Biosight team, including Dr. Liat Flaishon and Dr. Shoshi Tessler who lead our R&D activities, and Dr. Stela Gengrinovitch, the founder of the company. The excellent work and dedication of the entire Biosight team enabled the significant achievements. I would also like to thank our Board of Directors and Shareholders for their support over the years.” About the Proposed Merger Pursuant to the merger agreement, Advaxis will acquire all of the outstanding share capital of Biosight in exchange for the issuance of newly issued shares of Advaxis common stock upon closing, subject to the satisfaction or waiver of customary closing conditions, including the receipt of the required approval of the Advaxis stockholders and Biosight stockholders and certain regulatory approvals. Upon completion of the merger, Advaxis’s then-current equity holders will own approximately 25% and the former Biosight equity holders will own approximately 75% percent of Advaxis’s common stock, calculated on a fully diluted basis.